Introduction
============

With an incidence rate of 3.19/100,000, glioblastoma multiforme (GBM) is a highly malignant and notably aggressive primary tumour of the human brain, and the median survival time for patients is \<12 months in the majority of cases. The invasion of tumour cells into normal brain tissues means that it is difficult for surgery to achieve complete resection, and recurrence and mortality often occur. Different genetic aberrations arising from GBM lead to genetic heterogeneity of patient tumour cells, which infers resistance to additional therapies, including post-operative radiotherapy and chemotherapy ([@b1-ol-0-0-8055]--[@b3-ol-0-0-8055]). Epidermal growth factor receptor variant III (EGFRvIII) is one of the most common types of mutations of GBM and is responsible for various biological effects on the generation and development of tumours. Previous studies have indicated that this variation is significantly associated with poor prognosis in patients with GBM. Previously, numerous studies have indicated that EGFRvIII is associated with multiple characteristics of glioma stem cells, including self-renewal, abnormal differentiation, tumour initiation and treatment resistance. Studies have also indicated that high expression levels of EGFRvIII are positively correlated with the invasion abilities of GBM cells ([@b1-ol-0-0-8055],[@b4-ol-0-0-8055]). The amplification of EGFR is often accompanied by upregulated expression levels of EGFRvIII, which is significantly correlated with a short survival time for patients with BMG ([@b5-ol-0-0-8055],[@b6-ol-0-0-8055]). EGFRvIII is also expressed in other types of cancer, including lung cancer, but has not been identified in normal tissues or benign tumour tissues ([@b7-ol-0-0-8055]). Those tumours exhibiting activated EGFRvIII account for \~50% of patients with BMG ([@b8-ol-0-0-8055],[@b9-ol-0-0-8055]). These mutations are not detected in the normal brain tissues or in other normal tissues of adult humans ([@b10-ol-0-0-8055],[@b11-ol-0-0-8055]). Thus, due to its biological characteristics, EGFRvIII may serve as a good target for the gene therapy of GBM. If an antibody that specifically recognizes EGFR and induces apoptosis is designed, it may have the potential to effectively kill tumour cells through coupling with cytotoxic drugs. However, only limited studies exist on the molecular biology of EGFRvIII-associated mechanisms. Following continuous studies and the development of target drugs for clinical applications, the combination of surgery and chemoradiotherapy remains the main measure of current clinical therapies. Specifically, combined therapy using radiation treatment and temozolomide is the main regimen for GBM treatment. For GBM with the EGFRvIII mutation, the response to combined radiation treatment and temozolomide therapy remains unknown. To the best of our knowledge, there have been no studies investigating the mechanisms of the development of resistance. Therefore, the present study collected clinical materials and used a combination of *in vitro* and animal models to examine the effects of combined radiation treatment and temozolomide therapy on patients with GBM with the EGFRvIII mutation.

Materials and methods
=====================

### Cell lines and tissue samples

A total of 57 glioma patients with complete follow-up results who were treated between January 2013 and February 2014 in the Affiliated Hospital of Hebei University (Baoding, China) were randomly selected ([Table I](#tI-ol-0-0-8055){ref-type="table"}). Amongst the patients, 30 were men and 27 were women, with ages ranging from 22 to 76 years and a median age of 49 years. The Karnofsky Performance Status (KPS) scores for these patients ranged from 90 to 20 points, with a mean of 73 points. A total of 34 patients underwent a complete resection under surgical microscopy and 23 patients underwent a partial resection. A total of 26 patients exhibited tumors growing in the left brain and 31 patients exhibited tumors growing in the right brain. Post-operative pathological results indicated that 21 tumors were World Health Organization (WHO) grade I--II, 22 were WHO grade III and 14 were WHO grade IV ([@b11-ol-0-0-8055]). Statistical analyses were conducted on the clinical materials, and the Affiliated Hospital of Hebei University provided 32 tumor specimens preserved in liquid nitrogen. Amongst the 32 patients selected, 13 were men and 19 were women, with ages ranging from 23 to 71 years, with a mean age of 47 years. The post-operative pathological results indicated that 10 patients were WHO grade II, 5 patients were WHO grade II--III, 8 patients were WHO grade III and 9 patients were WHO grade IV, and 7 exhibited positive EGFRvIII results. The human GBM U87-EGFRvIII cell lines were obtained from Dr Webster Cavenee (Ludwig Cancer Institute, San Diego, CA, USA). The cells were grown in Dulbecco\'s modified Eagle\'s medium (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% fetal bovine serum (Invitrogen; Thermo Fisher Scientific, Inc.) and 0.4% Geneticin (G-418 sulphate; Gibco; Thermo Fisher Scientific, Inc.). The cells were incubated at 37°C in a 5% CO~2~ and 95% air environment until use. Approval for the use of the glioma samples was obtained from each patient and the present study was approved by the Ethics Committee of the Second Hospital of Tianjin Medical University (Tianjin, China).

### Cell Counting Kit-8 (CCK-8) assay

The cells were seeded in 96-well plates at a density of 5×10^3^ cells/well, with each well containing 100 µl cell suspension. Subsequent to cell attachment, temozolomide (Tasly Pharmaceutical Co., Ltd., Tianjin, China) was added at different concentration gradients (0.1 to 1, at intervals of 0.1 and 1 to 10, at intervals of 1). After 72 h, 10 µl CCK-8 reagent (Dojindo Molecular Technologies, Inc., Kumamoto, Japan) was added to each well, and the plates were incubated at 37°C for 4 h. The optical absorbance at 450 nm was measured on a microplate reader. The half maximal inhibitory concentration (IC~50~) result for 72 h was calculated using Origin 7.5 software (Microcal Software, Northampton, MA, USA). The IC~50~ of the U87-EGFRvIII cell line following 72 h of exposure to temozolomide, as measured by the CCK-8 kit was 5 mmol/l.

### RNA extraction and polymerase chain reaction (RT-PCR)

Total RNA from the patient GBM tissues was extracted using the TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer\'s protocol. The concentration and purity of RNA were determined using a NanoDrop^®^ ND-1000 spectrophotometer (Thermo Fisher Scientific, Inc.). The GoScript™ Reverse Transcriptase system (Promega Corporation, Madison, WI, USA) was used in complementary DNA synthesis according to the manufacturer\'s instructions. The expression levels of mature EGFRvIII were determined by semi-quantitative PCR using a PCR cycler (Nanjing KeyGenBiotech, Co., Ltd., Beijing, China) with a forward primer for the mature DNA sequence and a universal adaptor reverse primer as follows: Forward, 5′-TGACTCCGTCCAGTATTGATCG-3′ and reverse, 5′-GCCCTTCGCACTTCTTACACTT-3′ (Thermo Fisher Scientific Inc.). All PCR was performed using a PCR kit (PrimeSTAR^®^ Max DNA Polymerase; cat. no. R045A; Takara Biotechnology Co., Ltd., Dalian, China), according to the manufacturer\'s instructions. The PCR cycling conditions were as follows: 1 cycle at 95°C for 10 min; 35 cycles at 95°C for 30 sec, 58°C for 30 sec and 72°C for 1 min; and 1 cycle at 72°C for 10 min. The melting curve was obtained from 72--95°C. The data were derived from three independent experiments.

### Agarose gel electrophoresis

A 0.5% agarose gel was prepared, and poured onto a taped plate with casting combs in place. A total of 20--30 min was allowed for the gel to set. The tape and the gel casting combs were carefully removed, and the gel was placed in a horizontal electrophoresis apparatus. A 1XTris base, acetic acid and EDTA electrophoresis buffer was added to the reservoirs until the buffer covered the agarose gel. Loading dye (ethidium bromide) was added to each DNA sample, and the samples were mixed and placed into the wells. The gel was run at 150--200 mA until the required separation was achieved in 30 min. The DNA fragments were visualized on a long-wave ultraviolet light box and images were captured with a camera.

### Cell treatment

For the radiation treatment, collected cells were digested in a sterile 1.5-ml Eppendorf (EP) tube on a super clean bench and centrifuged for 5 min at \~63 × g (room temperature) with a tablet centrifuge. Subsequent to standing for 5 min at 37°C to collect the cells at the tip of the EP tube, T1 and T2 sequence images were collected via 1.5T nuclear magnetic resonance imaging (MRI) scans (Siemens AG, Munich, Germany). The data from the MRI scans were input into Gammaplan 5.3 (Leksell Perfexion Gamma Knife; Elekta Instrument AB, Stockholm, Sweden) to establish the most appropriate therapy for each patient. The cell-collecting site was wiped with 99% isodose, and 6-Gy peripheral doses were applied. Irradiation was applied with the Leksell Gamma Knife^®^ Perfexion™, and the cells were collected in 10-cm culture dishes for continuous culture under sterile conditions subsequent to irradiation. For temozolomide treatment, the cells were treated with temozolomide at the IC~50~ dose (5 mmol/l) for 24 h.

### Protein extraction and western-blot analysis

The cells were harvested 24 h after treatment, and the total protein from the glioma cell line was extracted using radioimmunoprecipitation assay lysis buffer with proteinase inhibitor. The homogenates were clarified by centrifugation at 20,000 × g and 4°C for 15 min, and the protein concentration was measured using the bicinchoninic acid method. A total of 40 mg protein mixed with 5X SDS loading buffer was loaded into each lane and separated by 10 or 12% SDS-PAGE. The separated proteins were transferred to polyvinylidene fluoride membranes (Roche Diagnostics, Basel, Switzerland), Membranes were blocked with 5% non-fat milk in PBST (1 h at 37°C), prior to incubation overnight at 4°C with primary antibodies against matrix metalloproteinase (MMP)-9 (1:1,000, cat. no. ab38898), and vascular endothelial growth factor (VEGF; 1:1,000, cat no. ab32152) (both from Abcam, Cambridge, UK) and EGFRvIII (rabbit monoclonal antibody, dilution 1:1,000; cat. no. sc-31156; Santa Cruz Biotechnology, Inc., Dallas, TX, USA) followed by incubation for 1 h at room temperature with a horseradish peroxidase-conjugated secondary antibody (cat. no. ZB2010, dilution 1:5,000; Zhongshan Bio Corp., Beijing, China). The membranes were washed in PBST. Subsequent to washing with stripping buffer, the membranes were re-probed with antibodies against GAPDH (dilution 1:5,000; cat. no. SC-47724; Santa Cruz Biotechnology, Inc.) at room temperature, overnight, and proteins were detected with an enhanced chemiluminescence detection system (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany).

### Intracranial animal model

In total, 3 groups of 4-week-old (15 g) female nude mice (Cancer Institute of the Chinese Academy of Medical Science). Each group contained 8 mice. Mice were kept at 2/cage at a constant temperature (24°C) with a 12-h light-dark cycle (dark period from 08:00 a.m. to 20:00 p.m.). The mice were fed (specific pathogen free mice food) once a day (20 g) and were intracranially implanted with 5×10^5^ U87-EGFRvIII cells to form the following groups: A group pre-treated with radiosurgery, a group treated with a combination therapy of 6 Gy radiosurgery and IC~50~ temozolomide, and a group with a negative control segment, using the Leksell Perfexion Gamma Knife. Bioluminescence imaging was used to detect intracranial tumour growth: Mice were anesthetized, injected intraperitoneally with D-luciferin (Promega Corporation) at 50 mg/ml. Images were captured with the IVIS Imaging System (Caliper Life Sciences; PerkinElmer, Inc., Waltham, MA, USA) for 10--120 sec. To quantify the bioluminescence, identical circular regions of interest were drawn around the entire head of each animal, and the integrated flux of photons, photons per second, in each region of interest was determined using the Living Images software package 3.2 (Caliper Life Sciences; PerkinElmer, Inc.). Data were normalized to the bioluminescence at the initiation of treatment for each animal. A tumour volume of 0.6 cm^3^ and a weight of 20 g were set as the humane end-points. All protocols involving animals were performed in accordance with an approved Institutional Animal Care and Use Committee protocol (Cancer Institute of the Chinese Academy of Medical Science).

### Immunohistochemistry analysis

Histological sections of tumour xenografts were excised and fixed in 10% neutral (4°C) buffered formalin for 3 days. Following paraffin embedding, 5-µm sections were cut. The paraffin-embedded tissue sections were used to examine EGFRvIII (cat. no. ab24293), EGFR (cat. no. ab52894), RAC-α serine/threonine-protein kinase (AKT-1; cat. no. ab81283), MMP-2 (cat. no. ab37150), MMP-9 (cat. no. ab38898) and X-ray repair cross-complementing protein 6 (Ku70; cat. no. ab92450) expression. Subsequent to de-waxing, sections were incubated with primary antibodies (all diluted to 1:100; and all provided by Abcam) overnight at 4°C, followed by incubation with abiotin-labelled secondary antibody (dilution 1:100; cat. no. SPN-9001; Zhongshan Bio Corp., Beijing, China) for 1 h at 37°C, incubation with diaminobenzidine for 2 h at room temperature, counterstaining with haematoxylin for 10 min at room temperature, dehydration and visualization using light microscopy (Olympus Corporation, Tokyo, Japan).

### Statistical analysis

SPSS software (v.16.0; SPSS Inc., Chicago, IL, USA) was used for all statistical analyses. One-way analysis of variance with a Tukey\'s post hoc test or was used to evaluate the differences between groups. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Statistical results from clinical data

The results ([Table II](#tII-ol-0-0-8055){ref-type="table"}) indicate that 26 (46%) patients were younger than the median age of 49 years, and 16 (28%) were older (P=0.426). A total of 23 patients were men (40%) and 19 were women (33%; P=0.590). The number of patients with a KPS score lower than the mean score of 70 was 16 (28%), and the number of patients with a KPS score higher than the mean score was 26 (46%; P=0.426). A total of 29 patients (51%), underwent complete tumour resection, and 13 (23%) patients underwent partial tumor resection (P=0.016). There were 19 patients with tumours growing on the left cerebral hemisphere (33%) and 23 patients with tumours growing on the right cerebral hemisphere (40%; P=0.924). The number of patients with a survival time of \<12 months, the median survival time was 30 (53%), and the number of patients with a survival time \>12 months was 12 (21%; P=0.009). The number of patients with WHO grades I--II was 12 (21%) and the number of patients with WHO grades III--IV was 30 (53%; P=0.030). Statistical analysis was performed on the data showing the levels of expression of EGFR and EGFRvIII from the pathology results of the tumours of 57 patients ([Table II](#tII-ol-0-0-8055){ref-type="table"}). From the 57 patients, 29 (51%) exhibited high expression of EGFRvIII. Of these patients, 20 and 9 were younger and older than the median age, respectively. In this group, 16 were men (28%), and 13 were women (23%; P=0.696). The number of the patients with a KPS score \<70, the mean score, was 8 (14%), and the number of patients with a KPS score \>70 was 21 (37%; P=0.227). A total of 17 patients (30%) underwent complete tumour resection and 12 (21%) patients underwent a partial tumour resection (P=0.872). A total of 16 patients exhibited tumours growing on the left cerebral hemisphere (28%) and 13 patients exhibited tumours growing on the right cerebral hemisphere (23%; P=0.140). The number of patients with a survival time less than the median survival time was 22 (39%) and the number of patients with a survival time greater than the median survival time was 7 (12%; P=0.022). The number of patients with WHO grades I--II was 7 (12%) and the number of patients with WHO grades III--IV was 22 (39%; P=0.043).

It was revealed that the expression of EGFR and EGFRvIII demonstrated no significant correlation with the patient age, gender, KPS score, and growth position. There was a significant correlation observed between range of surgical resection and high expression levels of EGFR, EGFRvIII, patient survival time and tumour grade. It was evident that the high expression of EGFR and EGFRvIII was negatively correlated with patient survival time and mostly occurred in high-grade glioma (P\<0.05 and P\<0.01, respectively).

### Agarose gel electrophoresis of tumour specimen PCR products

As indicated by the results from agarose gel electrophoresis ([Fig. 1](#f1-ol-0-0-8055){ref-type="fig"}), among the 32 patients with tumours, 9 patients (28%) experienced relatively marked expression of EGFRvIII, 1 (3%) of whom possessed a WHO grade II tumour and 8 (25%) of whom possessed a WHO grade III--IV tumour, which was not completely consistent with the data from the clinical pathology results. The reason for this observation maybe the position from which the tumour specimens were obtained. However, it was observed that the high expression of EGFRvIII was most common in high-grade glioma, indicating that high expression of EGFRvIII demonstrates a correlation with glioma malignancy.

### Expression of EGFRvIII, EGFR, AKT-1, MMP-2, MMP-9 and Ku70 in in vitro experiments

In addition to EGFRvIII as the typical marker for the cell invasion index, MMP may also be detected. Ku70 is a eukaryotic protein involved in the repair of DNA double-strand breaks by non-homologous end-joining ([@b12-ol-0-0-8055]), and maybe a critical biomarker for cancer cell sensitivity to DNA damage response. The results of western blot analysis ([Fig. 2](#f2-ol-0-0-8055){ref-type="fig"}) indicated that under radiation treatment at a low dose of 6 Gy, the expression levels of the EGFRvIII, AKT-1, MMP-2 and MMP-9 proteins in U87-EGFRvIII cell lines were upregulated to varying extents, with the exception of EGFR and Ku70. The results from these two markers requires additional study, which is generally consistent with the results reported in the literature that radiation treatment at low doses may lead to an increase in glioma cell invasiveness ([@b13-ol-0-0-8055]). However, subsequent to doubling of the radiation dose, the expression levels of the proteins demonstrated marked downregulation. Subsequent to radiosurgery in combination with temozolomide treatment at the IC~50~ dose, the expression levels of the EGFRvIII, EGFR, AKT-1, MMP-2, MMP-9 and Ku70 proteins in the EGFRvIII cell lines exhibited evident downregulation, and the combined therapy was able to reverse the condition in which the low dose of 6 Gy promoted the upregulated expression of the proteins. In the combined therapy group, the expression of EGFRvIII, EGFR, AKT-1, MMP-2, MMP-9 and Ku70 in the EGFRvIII cell lines was significantly lower compared with the simple radiosurgery or simple temozolomide treatment groups.

### U87-EGFRvIII cells in heterotransplantation models

In the heterotransplantation animal models, it was observed that in the U87-EGFRvIII cells treated by radiotherapy at the low dose of 6 Gy, the tumorigenicity was weaker compared with the cells treated with the negative control, which differed from the results of the *in vitro* experiments. Although radiation treatment at the low dose may promote the upregulation of expression of certain invasiveness indices of U87-EGFRvIII cells such as the AKT-1 and MMP-2, while it exhibits certain inhibitory effects on tumour proliferation. The mechanism is unclear, but in animal experiments in the present study, different doses of radiation therapy have a significant inhibitory effect on the growth of the tumour ([Fig. 3](#f3-ol-0-0-8055){ref-type="fig"}). And, the size of the tumours formed in the U87-EGFRvIII cells treated with the combination of radiosurgery and temozolomide were smaller compared with those in the cells treated with 6 Gy radiation. No significant change was observed in the weight of the nude mice in the combined treatment group, and their survival rate was higher compared with the nude mice with U87-EGFRvIII cells treated with the 6 Gy radiation treatment. The results from the immunohistochemical analysis of the tumour cells ([Fig. 3](#f3-ol-0-0-8055){ref-type="fig"}) in the heterotransplantation models indicated that the expression of EGFRvIII and Ki-67 in the tumour tissues subsequent to tumour formation in the U87-EGFRvIII cells treated with a combination of radiosurgery and temozolomide demonstrated a marked downregulation, and subsequent to combined treatment, the inhibition of MMP-9, VEGF and EGFRvIII was more evident. These results are different compared with those from the *in vitro* experiments, indicating that subsequent to the treatment of the U87-EGFRvIII cells, the proliferation and tumour formation abilities decreased significantly, and the invasion abilities of the formed tumours were also inhibited.

In the present study, the EGFRvIII mutation mostly occurred in GBMs with higher malignancies, and the combined treatment of radiosurgery and temozolomide may inhibit the invasiveness of tumour cells compared with other treatment regimens subsequent to tumour formation in the U87-EGFRvIII cells. The combined radiosurgery and temozolomide therapy also exerts a stronger inhibitory effect on the tumorigenicity of the U87-EGFRvIII cells in the brains of nude mice.

Discussion
==========

GBM is the one of most invasive types of tumours in the human brain. The invasion capabilities of these tumour cells results in difficulties in achieving a complete surgical resection of the tumour, and high rates of recurrence and mortality. Therefore, patients with GMB exhibit poor prognoses and notably short median survival times. The EGFR-targeting tyrosine kinase inhibitor possesses a high degree of immune activity, which is usually associated with drug resistance and may lead to chemotherapy failure. EGFR is the tyrosine kinase receptor on the cell surface and exhibits significantly high expression levels and mutations in GBM. The most common type of EGFR mutation is EGFRvIII: The deletion of exon 2 to 7, which leads to the fusion of exon 1 and 8 and produces tumour-specific surface antigens on the cell surface ([@b14-ol-0-0-8055],[@b15-ol-0-0-8055]). EGFRvIII has also been identified in other types of cancer, including lung, breast and prostate cancer, and may also be present in head and neck squamous carcinoma, but it is not exhibited in normal tissues or benign tumour tissues ([@b14-ol-0-0-8055]--[@b16-ol-0-0-8055]). The amplification of EGFR is often accompanied by the upregulated expression of EGFRvIII, which is significantly correlated with short survival times for patients with BMG. Previous studies have indicated that a high expression level of EGFRvIII is positively correlated with the invasion abilities of GBM cells. Previous studies have also indicated that 30--60% of GBM patients exhibit high expression levels of EGFRvIII, and these mutations are not detected in normal brain tissues of adult humans or other normal tissues ([@b17-ol-0-0-8055]--[@b19-ol-0-0-8055]). Therefore, EGFRvIII is a good target for GBM gene therapy. However, limited studies are available on the molecular biology of EGFRvIII-associated mechanisms ([@b20-ol-0-0-8055]--[@b22-ol-0-0-8055]). Numerous previous studies have examined the mechanisms and development of EGFRvIII-associated target drugs, such as the use of the protein Jagged 1-Notch signalling pathway and antibodies that specifically identify EGFR DNA oligonucleotide aptamers, among others, for the development of a more effective therapeutic regimen due to the poor effectiveness of current therapeutic tools ([@b21-ol-0-0-8055],[@b22-ol-0-0-8055]). At present, surgical resection combined with chemotherapy remains the best treatment, although it is difficult to implement the enhanced radiation treatment combined with temozolomide to improve the therapeutic effect ([@b23-ol-0-0-8055],[@b24-ol-0-0-8055]). In the present study, data from the clinical cases in the combined treatment group indicated that in the low-grade, WHO I--II, gliomas, 33% of the tumours possessed the EGFRvIII mutation. In the high-grade, WHO III--IV, gliomas, 61% of the tumours exhibited the EGFRvIII mutation. It was revealed that the probability of occurrence of high-grade glioma with the EGFRvIII mutation was greater, indicating that the EGFRvIII mutation was associated with tumour malignancy. PCR analysis of the tumour cells indicated that 9 patients (28%) exhibited EGFRvIII expression in tumour tissues, 1 (11%) of which possessed a WHO grade I--II tumour and 8 (89%) of which possessed WHO grade III--IV tumours. This proportion was lower compared with the results from pathological tests, which may be due to uncertainty in the sampling positions, but this method also illustrated the correlation between EGFRvIII mutation and tumour malignancy.

In the glioma radiation treatment group, the observation that therapeutic efficacy is positively correlated with radiation dose was verified. In the present study, the analysis of high-dose radiotherapy was not performed as the results are well established. In addition, under the conditions that normal brain tissues are protected and the radiation reactions are reduced, little improvement remains to be achieved in current radiotherapy measures ([@b25-ol-0-0-8055],[@b26-ol-0-0-8055]). Certain previous studies have indicated that radiation treatment at low doses between 5--8 Gy exhibits a promotional effect on the invasion abilities of tumour cells. Radiation treatment may promote the invasion abilities of glioma cells ([@b13-ol-0-0-8055],[@b27-ol-0-0-8055],[@b28-ol-0-0-8055]). Therefore, 6 Gy was selected as the dose for the present study to increase the invasion abilities of glioma. The results of the western blot analysis indicated that the 6-Gy dose may increase the expression levels of the EGFRvIII, EGFR, AKT-1, MMP-2, MMP-9 and Ku70 proteins in the U87-EGFRvIII cell lines, but subsequent to combined therapy with temozolomide, the expression levels of these proteins in the U87-EGFRvIII cell lines was significantly inhibited and was evidently lower compared with the normal negative control group. The animal experiments illustrated the marked difference. The 6-Gy radiation dose of the *in vitro* experiment increased the invasion capabilities of the U87-EGFRvIII cell lines, but the tumorigenicity and the invasive indices in the tumour tissues subsequent to tumour formation were not significantly improved and were inhibited, indicating that low-dose radiation, although increasing the invasiveness of the U87-EGFRvIII cells, did not significantly increase the rates of proliferation and the growth of the U87-EGFRvIII cells, but demonstrated an inhibitory effect. Subsequent to combined radiotherapy and temozolomide treatment, the tumour growth in the brains of the nude mice was significantly lower and the survival time was greatly extended compared with those in the negative control treatment group and the radiation-only treatment group. These results suggested that combined treatment with radiotherapy and temozolomide exhibits a clear inhibitory effect on the tumourigenicity of U87-EGFRvIII cells.

Overall, gene-targeted therapy based on molecular biology and epigenetics is a potential prospect for GBM treatment, but the application of this approach in clinical treatment is not available at present. Therefore, to improve the existing treatment options and to enhance the efficacy of current therapeutics, the development of more accurate radiotherapy treatments or the use of additional chemotherapeutical drugs, including bevacizumab and valproic acid (VPA) ([@b29-ol-0-0-8055]--[@b31-ol-0-0-8055]), should be investigated alongside the development of novel therapeutic techniques and treatments.

The temozolomide was donated by Tasly Pharmaceutical Co., Ltd. (Tianjin, China).
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![(A) Agarose gel electrophoresis of tumour polymerase chain reaction products. \*Indicates the tumours expressing EGFRvIII. (B) Post-operative histology of EGFR and EGFRvIII tumours. EGFR, epidermal growth factor receptor; EGFRvIII, EGFR variant III mutation; N, ddH~2~O negative control; P, EGFRvIII amplification product control; M, marker.](ol-15-04-5751-g00){#f1-ol-0-0-8055}

![*In vitro* expression of EGFRvIII, EGFR, AKT-1, MMP-2, MMP-9 and Ku70. (A) Levels of expression of EGFRvIII, EGFR, AKT-1, MMP-2, MMP-9 and Ku70 proteins *in vitro* in U87-EGFRvIII cell lines treated with negative control, 6 Gy radiation, 12 Gy radiation, and combined treatment of 6 Gy radiosurgery and temozolomide. (B) Schematic diagram illustrating the combined treatment of radiosurgery and temozolomide. EGFR, epidermal growth factor receptor; EGFRvIII, EGFR variant III; AKT-1, RAC-α serine/threonine-protein kinase; MMP-2, matrix metalloproteinase 2; MMP-9; Ku70, X-ray repair cross-complementing protein 6; GMB, glioblastoma multiforme; DMSO, dimethyl sulphoxide; TMZ, temozolomide.](ol-15-04-5751-g01){#f2-ol-0-0-8055}

![U87-EGFRvIII cell line in heterotransplantation models treated with negative control, 6 Gy radiation, and combined treatment with radiosurgery and temozolomide. (A) Bioluminescence images from heterotransplantation models (magnification, ×40) treated with negative control, 6 Gy radiation (48 h after treatment with 6 Gy peripheral doses by radiosurgery with 99% of isodose) and combined treatment with radiosurgery and temozolomide (cells were treated for 24 h with temozolomide at the IC~50~ dose for 24 h after 6 Gy radiation) at 7, 14 and 21 days subsequent to tumour development. (B) Histological sections of tumor xenografts were excised and fixed in 10% neutral buffered formalin. Following paraffin embedding, 5-µm sections were cut and dried, deparaffinized, and rehydrated. Next, the nonspecific binding sites were blocked, and the slides were incubated at 4°C overnight in a 1:100 dilution of primary antibodies. Finally, the slides were incubated with a secondary antibody for 30 min. Immunohistochemistry for EGFRvIII and Ki-67 on xenograft tumour sections (Scale bar, 100 µm). (C) Evaluation of tumour growth curves. (D) Evaluation of weights of mice. (E) Improved survival observed in mice treated with the combined therapy. H&E, hematoxylin and eosin; TMZ, temozolomid; EGFRvIII, epidermal growth factor receptor variant III.](ol-15-04-5751-g02){#f3-ol-0-0-8055}

###### 

Patient characteristics (n=57).

  Characteristic                           Value
  ---------------------------------------- -------------
  Median age at diagnosis (range), years   49 (22--76)
  Age groups by years, n (%)               
    18--39                                 37 (65)
    40--49                                 10 (18)
    50--59                                 3 (5)
    60--69                                 4 (7)
    \>70                                   3 (5)
  Sex                                      
    Male                                   30 (53)
    Female                                 27 (47)
  KPS score                                
    Average                                73
    Range                                  20--90
    ≤70, n (%)                             20 (35)
    \>70, n (%)                            37 (65)
  Surgery                                  
    Total resection                        34 (60)
    Partial resection                      23 (40)
  Side                                     
    Left                                   26 (46)
    Right                                  31 (54)
  Survival, months                         
    Average                                11.2
    Range                                  2--39
    \<12, n (%)                            35 (61)
    ≥12, n (%)                             22 (39)
  WHO grade                                
    I--II                                  21 (37)
    III                                    22 (39)
    IV                                     14 (25)

WHO, World Health Organization; KPS, Karnofsky performance status.

###### 

Associations between clinic pathological features and EGFR and EGFRvIII status (n=57).

  Characteristic        EGFR-positive, n (%)   P-value                                              EGFRvIII-positive, n (%)   P-value
  --------------------- ---------------------- ---------------------------------------------------- -------------------------- ----------------------------------------------------
  Patients              42 (74)                                                                     29 (51)                    
  Age, years                                                                                                                   
    18--49              26 (46)                0.426                                                20 (35)                    0.514
    50--76              16 (28)                                                                     9 (16)                     
  Sex                                                                                                                          
    Male                23 (40)                0.590                                                16 (28)                    0.696
    Female              19 (33)                                                                     13 (23)                    
  KPS score                                                                                                                    
    ≤70                 16 (28)                0.426                                                8 (14)                     0.227
    \>70                26 (46)                                                                     21 (37)                    
  Surgery                                                                                                                      
    Total resection     29 (51)                0.016^[a](#tfn2-ol-0-0-8055){ref-type="table-fn"}^   17 (30)                    0.872
    Partial resection   13 (23)                                                                     12 (21)                    
  Side                                                                                                                         
    Left                19 (33)                0.924                                                16 (28)                    0.140
    Right               23 (40)                                                                     13 (23)                    
  Survival, months                                                                                                             
    \<12                30 (53)                0.009^[b](#tfn3-ol-0-0-8055){ref-type="table-fn"}^   22 (39)                    0.022^[a](#tfn2-ol-0-0-8055){ref-type="table-fn"}^
    ≥12                 12 (21)                                                                     7 (12)                     
  WHO grade                                                                                                                    
    I--II               12 (21)                0.030^[a](#tfn2-ol-0-0-8055){ref-type="table-fn"}^   7 (12)                     0.043^[a](#tfn2-ol-0-0-8055){ref-type="table-fn"}^
    III--IV             30 (53)                                                                     22 (39)                    

P\<0.05

P\<0.01. EGFR, epidermal growth factor receptor; EGFRvIII, EGFR variant III; WHO, World Health Organization; KPS, Karnofsky performance status.

[^1]: Contributed equally
